Clinical Trial

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

Study acronym: Tumor HI
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-03-14; most recent amendment 2026-05-15.
Status change: Not Yet Recruiting → Recruiting 2025-05-01
Trial Details
NCT Number NCT06881992
Lead Sponsor Rezolute
Conditions Tumor Hyperinsulinism (Tumor HI)
Enrollment 16 participants
Start Date 2025-04-16
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-18